October 22, 2024 03:29 PM EDTUpdated 05:09 PM
China
Pharma
Law

Lawyers pre­dict Biose­cure pas­sage in lame duck ses­sion, but Sen­ate may de­cide key de­tails

Zachary Brennan

Senior Editor

BETHES­DA, MD — A pan­el of DC-fo­cused lawyers pre­dict­ed that the an­ti-Chi­na Biose­cure Act is like­ly head­ed for fi­nal pas­sage dur­ing the con­gres­sion­al “lame duck” pe­ri­od …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Up­dat­ed: Pfiz­er's ac­tivist says board must 'hold man­age­ment ac­count­able' for R&D short­com­ings

Sang­amo to seek ac­cel­er­at­ed ap­proval for Fab­ry gene ther­a­py, claims it won't need con­fir­ma­to­ry study

Ahead of No­vo’s Ca­griSe­ma read­out, Lil­ly re­turns to a promis­ing new class of obe­si­ty drugs

Be Bio rais­es $82M to fund work on B cell ther­a­py in he­mo­phil­ia B

Am­gen preps to launch Eylea biosim­i­lar years ear­ly af­ter Re­gen­eron los­es ap­peal

sponsored

IDEAYA Bio­sciences: Tar­get­ing un­met mar­ket needs with pre­ci­sion on­col­o­gy

A service from the Financial Times